

<b>Academic Year 2011-2012</b>	
<b>Dec 05 2012</b>	Speaker: Scot Diegel - Major Depressive Disorder (in Children and Adolescence), Overview of the Pristiq Phase III Pediatric Trials
<b>Nov 14 2012</b>	Speaker: Brian Traver - Topics from the 2012 Sensible Guidelines Symposium.
<b>Oct 3 2012</b>	Speaker: Marian Fisher - ATLAS Challenge: Missing Data & Questionable Quality.
<b>May 2 2012</b>	Speaker: Shuang Huang - Introduction to Item Response Theory Modeling with Application to a Study of Alcohol and Marijuana Dependences.
<b>Apr 11 2012</b>	Speaker: Kathryn Schurr - Osteoporosis Clinical Trials with Fracture Outcomes
<b>Mar 17 2012</b>	Speaker: Weiqun Tong - Introduction to Pharmacokinetic Data
<b>Feb 1, 2012</b>	<b>**Cancelled**</b>
<b>Jan 11, 2012</b>	Speaker: John Kloke - Systematic Review and Meta-analyses
<b>Dec 7, 2011</b>	Speaker: Tom Cook - From the SDAC Archives: The WIZARD Trial
<b>Nov 2, 2011</b>	Speaker: Allison Furey - JAK Kinase Inhibitors: Disease Areas Targeted and Issues Surrounding Selectivity
<b>Oct 5, 2011</b>	Speaker: Robin Bechhofer - Recent Trials of Novel Anticoagulants in Atrial Fibrillation
<b>Sept 14, 2011</b>	Speaker: Melissa Schultz - Teplizumab for Treatment of Type 1 Diabetes: Results of the Protege Study
<b>Academic Year 2010-2011</b>	
<b>May 4, 2011</b>	Speaker: Jan Feyzi
<b>April 6, 2011</b>	Speaker: Gabriel Nicholas
<b>March 2, 2011</b>	<b>**Cancelled**</b> - Speaker: Michelle Detry
<b>Feb 9, 2011</b>	Speaker: Scott Diegel - Reproducible Research: Some Issues and Possible Solutions
<b>Dec 1, 2010</b>	Speaker: Kevin Rubin - The Ethics of Placebo-Controlled

<b>Dec 1, 2010</b>	Speaker: Kevin Bunr - The Ethics of Placebo-Controlled Trials
<b>*Tuesday * Nov 9, 2010</b>	Speaker: Brian Traver - An Overview of CDISC (Clinical Data Interchange Standards Consortium)
<b>Nov 3, 2010</b>	Speaker: Tom Cook (continuing his presentation from October)
<b>Oct 13, 2010</b>	Speaker: Tom Cook - From the SDAC Archives: Some Issues Associated with the ACTS and THS Trials
<b>Sept 8, 2010</b>	Marian Fisher - Wisdom from Wittes: "Missing Inaction," "On Looking at Subgroups"
<b>Academic Year 2009-2010</b>	
<b>May 10, 2010</b>	Deedra Nicolet - Background for PEARL Trial Overview of Schizophrenia and Bipolar Disorder
<b>April 7, 2010</b>	Allison Furey - Tolvaptan: A Survey of Potentially Treatable Diseases and Associated Clinical Trials
<b>March 3, 2010</b>	Melissa Schultz - Current Approaches to Therapy for Type 1 Diabetes
<b>Feb 3, 2010</b>	Robin Bechhofer - Issues in Clinical Trials Data Monitoring  *Please note: Attendees will be encouraged to share examples and experiences based on trials in the SDAC portfolio.
<b>Jan 6, 2010</b>	Jan Feyzi - CORONA: The Final Year  *Please note: Results of the trial will not be presented in detail; however, you may want to review the primary manuscript for background information. <a href="#">Detailed Trial Results</a>
<b>Dec 2, 2009</b>	Gabriel Nicholas - FDA Reviewer Guidance: "Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review"
<b>Nov 4, 2009</b>	Michelle Detry - Adaptive Randomization: An Overview of the Pros and Cons
<b>Oct 7, 2009</b>	Scott Deigel - Medical Coding and Classification Systems for Clinical Trials: A High Level Overview
<b>Academic Year 2008-2009</b>	

**Academic Year 2008-2009**

<b>Jan 7, 2009</b>	Septmeber 2008 example of "Who Knows What and When?"
<b>Feb 4, 2009</b>	Some Comments on Causality
<b>March 25, 2009</b>	Results of the ILLUMINATE Trial
<b>April 8, 2009</b>	The Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF) Trial: "Rationale, Design and Challenges"
<b>May 9, 2009</b>	A Prospective, Randomized Trial Comparing the Efficacy of Anidulafungin and Voriconazole in Combination to that of Voriconazole Alone When Used for Primary Therapy of Proven or Proabable Invasive Aspergillosis

**Academic Year 2007-2008**

<b>Oct 3</b>	Scott Diegel
<b>Nov 7</b>	Ellen Roecker - Clinical Trialists' Journey to the Last Frontier
<b>Dec 5</b>	Michelle Detry
<b>*Monday* Feb 11</b>	Robin Bechhofer - Patient-Reported Outcome Measures: Selected Regulatory Issues
<b>Mar 5</b>	Jan Feyzi
<b>Apr 2</b>	Marian Fisher
<b>May 7</b>	Melissa Schultz

**Academic Year 2006-2007**

<b>Dec 13</b>	Anti CD3 Monoclonal Antibody in New-onset Type I Diabetes
<b>Feb 7</b>	A 1-year Extension to the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial
<b>April 18</b>	CB1 Inhibition in the Treatment of Obesity

**Academic Year 2005-2006**

<b>May 10</b>	The Rationale and Design of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT Trial)
---------------	--

<b>March 1</b>	The Search for an Association between Statins and Cancer Risk
<b>Feb 1</b>	Combining Information across Studies: Methods, Pitfalls, and Limitations
<b>Dec 7</b>	FDA Advisory Meeting (Arthritis Committee, Drug Safety and Cancer Risk Management Committee): February 16-18, 2005
<b>Nov 2</b>	The Studies of Oral Enoximone Therapy in Advanced Heart Failure (ESSENTIAL): Design and Final Results
<b>Oct 5</b>	Advanced Issues in the Design and Conduct of Randomised Clinical Trials- A Discussion of the Oxford International Symposium
<b>Academic Year 2004-2005</b>	
<b>May 18</b>	Tolvaptan in Patients with Congestive Heart Failure: Background and Design of the Everest Trial
<b>April 6</b>	The TNT (Titrating to New Targets) Study: ACC Presentation and Review of the Monitoring Process
<b>March 16</b>	Basic Issues in Gene Therapy
<b>Dec 1</b>	Liability in the Data Monitoring Process
<b>Nov 3</b>	Clinical Trials in Pulmonary Arterial Hypertension
<b>Oct 6</b>	The Comparison of Medical therapy, Pacing, AND defibrillation in heart failure (COMPANION) Trial: Final Results and FDA Review
<b>Academic Year 2002-2003</b>	
<b>May 9</b>	Title: Celecoxib, a COX-2 Inhibitor, in Cancer Prevention
<b>April 9</b>	Title: The Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) Trial
<b>March 5</b>	'The Age-Related Eye Disease Study (AREDS)'
<b>Feb 5</b>	Results of the ALLHAT Trial'
<b>Dec 4, 2002</b>	'Discussion of Results from the Women's Health Initiative Estrogen Plus Progestin Trial'

<b>Nov 6, 2002</b>	'Cholesterol Lowering with Statins: Effect on Cardiovascular Disease'
<b>Oct 2</b>	'Precursor Studies of ADOPT (A Diabetes Outcome Progression Trial)'
<b>Academic Year 2001-2002</b>	
<b>May 1</b>	Results of the Endothelin Antagonism with Bosentan and Lowering of Events (ENABLE) Trial
<b>April 3</b>	The WIZARD Trial
<b>March 6</b>	The Val-HEFT Trial: Angiotensin-Receptor Blockade in Congestive Heart Failure
<b>Feb 6</b>	Managing and Monitoring Multicenter Clinical Trials: Who is in charge of what?
<b>Jan 9</b>	FDA Draft Guidance for Clinical Trial Sponsors On the Establishment and Operation of Clinical Trial Data Monitoring Committees
<b>Dec 5</b>	Pacemakers, Defibrillators and the Companion Trial
<b>Nov 7</b>	Paradoxes in Equivalence Trials
<b>Oct 10</b>	Stroke Prevention in Patients with Atrial Fibrillation
<b>Academic Year 2000-2001</b>	
<b>May 2</b>	The PRAISE I and PRAISE II Trials
<b>April 4</b>	"Uninformed Consent: What Patients at the 'Hutch' Weren't Told About Experiments in Which They Died"
<b>Feb 14</b>	The Sharing of Information Between Data Safety Monitoring Boards.
<b>Jan 10</b>	A Brief Overview of 30 Years of Experience with Cholesterol-Lowering Trials. Part III.
<b>Nov 1</b>	A Brief Overview of 30 Years of Experience with Cholesterol-Lowering Trials. Part II.
<b>Oct 11</b>	A Brief Overview of 30 Years of Experience with Cholesterol-Lowering Trials. Part I.
<b>Sept 6</b>	A Carvedilol Update: Mortality Results of the COPERNICUS Trial

